Allogene Therapeutics R&D Showcase Features Hematologic and Solid Tumor Advances Across its AlloCAR T™ Platform
Hematology Franchise: Lead CD19 and BCMA Programs Demonstrated Deep, Durable Responses CD19 Program: Phase 1 Studies Support Ongoing ALLO-501A Potentially Pivotal Phase 2 Trial in Relapsed/Refractory (R/R) Large B Cell…
Allogene Therapeutics Unveils Novel Approach to Generate Engineered AlloCAR T™ Cells to Control Immune Rejection at the Annual Meeting of the Society for Immunotherapy of Cancer
Promising Preclinical Data Highlights a Simple One-Step Gene Editing Strategy to Prevent the Rejection of AlloCAR T™ Cells by Host T Cells and NK Cells Cloaking Approach Demonstrates Superiority to B2M…
Allogene Therapeutics To Host Research & Development Showcase and Participate in Five Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif. , Nov. 09, 2022 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products…
- 1
- 2
- 3
- 4
- …
- 9
- Go to the next page